Daiwa Securities Initiates Coverage on HUTCHMED With Buy Rating, $23 Price Target
Hutchmed to Receive $10 Million Milestone Payment Through Takeda
Express News | Reported Earlier, HUTCHMED to Receive $10M Payment From Takeda As FRUZAQLA Achieves First National Reimbursement In Europe For Metastatic Colorectal Cance
Hutchmed (China) (00013.HK): Following the first inclusion of FRUZAQLA (fruquintinib) in the healthcare insurance in Europe, a milestone payment from Takeda will be received.
Gelonghui reports on December 13 that Hutchmed (China) (00013.HK) announced it will receive a $10 million milestone payment from its partner Takeda (TSE: 4502/NYSE: TAK). Takeda has received a recommendation in December 2024 for FRUZAQLA to be included in public medical coverage for patients with previously treated metastatic colorectal cancer in Spain, marking the first recommendation for public medical coverage obtained in Europe. Colorectal cancer is the second leading cause of cancer-related deaths in Europe. FRUZAQLA received approval from the European Commission in June 2024.
Reported Earlier, HUTCHMED's ORPATHYS and TAGRISSO Combo Gains Therapy Designation in China for Advanced Lung Cancer
Hutchmed (China) (00013.HK) announced that the combination therapy of Orpathys and Tagrisso has been included as a breakthrough therapy in China for the treatment of specific lung cancer patients with disease progression after EGFR inhibitor treatment.
On December 12, Glonghui reported that Hutchmed (China) (00013.HK) announced today that the Drug Evaluation Center of the National Medical Products Administration of China ("National Drug Administration") has included Orpathys (savolitinib) and Tagrisso (osimertinib) in the list of breakthrough therapeutic drugs, for the treatment of patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer who have progressed after receiving epidermal growth factor receptor ("EGFR") inhibitors, accompanied by MET amplification. Orpathys is
